IMA Co-Founder and Chief Scientific Officer Dr. Paul Marik hosts journalist and filmmaker John Davidson to reveal the shocking truths behind Hydroxychloroquine censorship. Davidson’s award-winning documentary, Epidemic of Fraud, exposes the orchestrated efforts to discredit this powerful repurposed medicine and uncovers the influential powers behind the attempted takedown.

She and her husband both got COVID in August 2021. Fortunately she had a great doctor. Watch this quick MyStory now.

This study from Belgium demonstrates that the use of standard/low dose hydroxychloroquine and azithromycin in hospitalized COVID-19 patients reduces the risk of mortality by 35%.

"Hydroxychloroquine was known very early to be effective and they tried to demolish that right out of the gate," Dr. Pierre Kory.

When the pandemic began in early 2020, through research, Dr. John found that several doctors around the world were seeing success treating COVID-19 with hydroxychloroquine. After having treated over 5000 patients he received a registered letter from my state medical officer. His license was at risk. Watch his story now.

We are not aware of any interactions between ivermectin and hydroxychloroquine and believe it is safe to take them together. However, it is important to ask your own physician, as every individual is different. You can also look here for the database of lists of drug reactions with Ivermectin from drugs.com.

Authors: Peterson DJ. PMID: Abstract Keywords: Source: https://ago.nebraska.gov/sites/ago.nebraska.gov/files/docs/opinions/21-017_0.pdf Archive: https://archive.is/EoVhB

Authors: Cadegiani FA, Goren A, Wambier CG, McCoy J PMID: 34249367 PMCID: PMC8262389 DOI: 10.1016/j.nmni.2021.100915 Abstract In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further [...]

Authors:Seet RC, Quek AM, Ooi DS, Sengupta S, Koo CY. PMID:PMC8056783 DOI: 10.1016/j.ijid.2021.04.035 Abstract Background: We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19). Methods: An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined [...]

Objective: To determine if hydroxychloroquine (HCQ) reduces the incidence of new illness, hospitalization or death among outpatients at risk for or infected with SARS-CoV-2 (COVID-19).